J&J Forecasts Record-breaking Revenue And Robust Innovation
Meanwhile Seniors Save Billions From Negotiated Prices, Thanks To A Law Passed By Democrats Without A Single Republican Vote
SHOT: Big Drug Companies And Their Republican Allies Forecasted Doom And Gloom If Medicare Was Given The Power To Negotiate Prices. “The IRA threatens to deliver disaster across the entire innovation, financing and distribution system for prescription drugs.” – Joe Grogan, Former Trump White House Director of Domestic Policy [The Hill, 12/23/23]
CHASER: J&J Projects $100+ Billion In Revenue In 2026, The First Year Seniors And Taxpayers Save Billions From Democrats’ Negotiated Drug Prices. “In 2025, we invested over $32 billion in R&D and M&A including the acquisitions of Intracellular Therapies and Halda Therapeutics. We also initiated billions of dollars in new state-of-the-art manufacturing facilities in the US, which will accelerate the delivery of our next wave of innovation…And we have line of sight to double-digit growth by the end of the decade which is notable as Johnson & Johnson is the only healthcare company that will soon deliver more than $100 billion in annual revenue.” – Joaquin Duato, CEO of Johnson and Johnson [Motley Fool, 1/21/26]
LIME: Trump Handed Big Pharma A Multi-Billion Dollar Bailout In His Big, Ugly Bill, Carving Out Top-Selling Products From Negotiation And Raising The Prices Of Lifesaving Drugs For Seniors, Including J&J’s Darzalex. “DARZALEX is the largest medicine by sales in our pharmaceutical portfolio and is considered the foundational gold standard treatment in multiple myeloma. With annual sales over $14 billion, DARZALEX grew an impressive 22% across the full year.” – Joaquin Duato, CEO of Johnson and Johnson [Motley Fool, 1/21/26]